Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of ABP-700 for procedural sedation in adults undergoing colonoscopy
2015-004019-19Phase 2Terminated
- Sponsor
- The Medicines Company
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of moxetomidate (2 arms), sponsored by The Medicines Company. Primary endpoints: Dose-response relationship of ABP-700 for procedural sedation, Efficacy of ABP-700 for procedural sedation and 1 more. Started Apr 2016; status: terminated.
02
Drugs
moxetomidate
Beyond the preview
Go deeper on 2015-004019-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004019-19.